Effect of leukemia treatment on blood sugar and cholesterol
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how a type of leukemia treatment called tyrosine kinase inhibitors affects blood sugar and cholesterol levels in people with chronic myeloid leukemia. It may help doctors understand and manage these side effects better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic myeloid leukemia (CML).
- You have no other major medical conditions (meaning you are generally healthy aside from CML).
- You do not have diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your current leukemia medicines and herbal or plant-based products may interact, and how that could affect outcomes in chronic myeloid leukemia. It may help doctors better understand which drug combinations are safest and most effective.
This study compares two different medicines for people with chronic myeloid leukemia (CML) whose current treatment with imatinib (Gleevec) has not worked well enough. It tests whether switching to dasatinib (Sprycel) or increasing the dose of imatinib to 600 mg helps get the disease under better control.
This study looks at how TKI medications, used to treat chronic myeloid leukemia (CML), may affect thyroid function. It will track patients starting TKI therapy to see if thyroid problems develop.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This study looks at how blood and clotting are affected in people newly diagnosed with acute myeloid leukemia (AML) who receive a common intensive chemotherapy combination (idarubicin and cytarabine). The goal is to better understand blood-related side effects and improve care.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.